OPKO Health, Inc.
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that…
Medical - Diagnostics & Research
US, Miami [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -74.60 | 12.68 | 49.95 | |
| Graham Fair Price | 56.44 | 1.28 | 0.82 | |
| PEG | -87.19 | -0.03 | 0.24 | |
| Price/Book | 19.99 | 0.74 | 0.61 | |
| Price/Cash Flow | 52.23 | -12.17 | -25.48 | |
| Prices/Earnings | -50.03 | 10.40 | -20.80 | |
| Price/Sales | 26.63 | 5.96 | 4.71 | |
| Price/FCF | 52.23 | -12.17 | -25.48 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Positive
Fundamentals
Profitability
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 34.81 | 0.23 | 0.17 | |
| Operating Margin | -75.81 | 0.08 | -0.34 | |
| ROA | 111.96 | 0.01 | < 0.005 | |
| ROE | < 0.005 | 0.02 | 140.14 | |
| ROIC | -0.04 | 0.01 | -69.53 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.90 | -0.36 | 151.91 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.14 | 1.23 | 797.24 | |
| EPS QOQ | 0.88 | 3.41 | 289.22 | |
| FCF QOQ | 0.16 | -1.53 | 860.62 | |
| Revenue QOQ | 0.05 | -0.05 | -4.06 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 35.86 | 40.05 | 11.67 | |
| Days Sales Outstanding (DSO) | 57.31 | 71.87 | 25.41 | |
| Inventory Turnover | 2.51 | 2.25 | -10.45 | |
| Debt/Capitalization | 0.13 | 0.24 | 89.13 | |
| Quick Ratio | 1.36 | 2.69 | 98.60 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Book Value | 2.00 | 2.02 | 0.96 | |
| Cash | 0.06 | 0.59 | 905.31 | |
| Capex | 0.01 | 0.01 | 10.39 | |
| Free Cash Flow | -0.05 | -0.12 | -153.57 | |
| Revenue | 0.26 | 0.25 | -4.34 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad